Category: Patent & Other IP Offices
-
AIA & AIA: Director Squires issues America’s Innovation Agency memo to take charge of IPR institution decisions under America Invents Act
USPTO Director John A. Squires wants to put an end to the PTAB’s tendency to institute IPRs for career and institutional motives.
-
USPTO Director Squires proposes rules that would marginalize PTAB IPRs: market value of “born strong” U.S. patents to rise
Director Squires has proposed new rules for the PTAB that do not merely complicate but simply prevent serial challenges to patent, even on different grounds. And not only that.
-
Samsung ordered to pay $445 million in U.S. wireless standards-related infringement dispute: jury verdict
The Eastern District of Texas has issued a jury verdict ordering Samsung to pay over $445 million in damages for infringing four of non-practising entity Collissionâs wireless communication standard-essential patents.
-
Squires on fire: revived patent post-PTAB, declared expert unreliable, took procedural route that may have closed door to appeal
Based on an expert’s lack of credibility in his eyes, Director Squires not only terminated the PTAB proceedings without a remand but also made it difficult (or impossible) to appeal,
-
USPTO director Squires greenlights deputy Morgan Stewartâs PTAB discretionary denial program
John A. Squires, who took over as United States Patent and Trademark Office director last month, has issued a Delegation of Authority for deputy director Coke Morgan Stewart to continue the recently reinstated Patent Trial and Appeal Board discretionary denial program.
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Officeâs Patent Trial and Appeal Board decision that deemed one of Bayerâs rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
UK government proposes SEP measures such as rate-setting procedure, seeks input
The UK Intellectual Property Office has invited stakeholders from across the SEP ecosystem to submit views and evidence on proposed SEP measures by October 7, 2025.
-
USPTO divisionsâ clash over Apple patent invalidation decision undermines âintegrity and consistencyâ, patentee alleges
A petition filed by Proxense against Apple has uncovered an inconsistency in results on substantially similar issues and the same underlying facts between decisions by the United States Patent & Trademark Officeâs Patent Trial and Appeal Board and fellow internal division, the Central Reexamination Unit.
-
EPO’s Enlarged Board of Appeal: reproducibility irrelevant to eligibility of sold product as prior art and ability to destroy novelty
Context: The Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) made a decision on claim construction last month that aligns its case law with that of the Unified Patent Court’s (UPC) Court of Appeal (CoA) (June 18, 2025 ip fray article). We will continue to report on EBA decisions that we believe…